background image

Paid Clinical Trials Gilbert

Discover 1,250 paid clinical trials in Gilbert, Arizona. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter
2
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: 10 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase1, Phase2, Recruiting
Active & Responsive

Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine

for
Migraine
Location: 89 recruiting locations
Sponsor: AbbVie

Sex: Female

Age: 18+

Code: NCT06417775

Phase3, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: 13 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

for
Leukemia, Myeloid, Acute
Location: 21 recruiting locations
Sponsor: OncoVerity, Inc.

Sex: All

Age: 18+

Code: NCT06384261

Phase2, Recruiting
Active & Responsive

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

for
Metastatic Breast Cancer
Location: 56 recruiting locations
Sponsor: American Society of Clinical Oncology

Sex: All

Age: 65+

Code: NCT06377852

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: 12 recruiting locations
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06051695

Phase1, Phase2, Recruiting
Active & Responsive

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

for
Carcinoma, Non-Small-Cell Lung
Location: 44 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06623422

Phase3, Recruiting
Active & Responsive

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

for
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma,
Location: 15 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05458297

Phase2, Recruiting
Active & Responsive

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

for
Carcinoma, Non-Small-Cell Lung
Location: 12 recruiting locations
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT04165798

Recruiting
Active & Responsive

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

for
Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis,
Location: 8 recruiting locations
Sponsor: Institut de Recherches Internationales Servier

Sex: All

Age: 18+

Code: NCT05786924

Phase1, Phase2, Recruiting